Eiger BioPharmaceuticals, Inc.
EIGRQ Healthcare Biotechnology
Eiger BioPharmaceuticals, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $15.8 million, up 17.0% from fiscal 2022. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow EIGRQ
Eiger BioPharmaceuticals, Inc. (EIGRQ) Piotroski F-score
Eiger BioPharmaceuticals, Inc.'s Piotroski F-score for fiscal 2023 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2023 | 4 | — |
How fiscal 2023’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (94.31%) | (78.51%) | Fail | 0 |
| Positive operating cash flow | (74.55m) | (83.01m) | Fail | 0 |
| Rising return on assets | (94.31%) | (78.51%) | Fail | 0 |
| Cash flow above net income | 415.00k | 13.77m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.32 | Pass | 1 |
| Rising current ratio | 0.71 | 4.68 | Fail | 0 |
| No new shares issued | 1,476,000 | 1,388,000 | Fail | 0 |
| Rising gross margin | 99.85% | 86.38% | Pass | 1 |
| Rising asset turnover | 0.20 | 0.11 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| EIGRQ Eiger BioPharmaceuticals, Inc. | 4 |
| VBIO Valion Bio, Inc. compare | 3 |
| BIORQ Biora Therapeutics, Inc. compare | 2 |
| NTBLQ Notable Labs, Ltd. compare | 2 |
| MTNB Matinas Biopharma Holdings, Inc. compare | 1 |
| SLXN Silexion Therapeutics Corp compare | — |
| XRTX XORTX Therapeutics Inc. compare | — |
| GOVX GeoVax Labs Inc. compare | — |
| ELAB PMGC Holdings Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover